Michael D Altman

发表

A "Reverse-Schur" Approach to Optimization With Linear PDE Constraints: Application to Biomolecule Analysis and Design.

Jacob K. White, Jaydeep P Bardhan, Jacob K White, 2009, Journal of chemical theory and computation.

Additivity in the analysis and design of HIV protease inhibitors.

Bruce Tidor, Michael K Gilson, Akbar Ali, 2009, Journal of medicinal chemistry.

Numerical integration techniques for curved-element discretizations of molecule-solvent interfaces.

Jacob K. White, Bruce Tidor, Jaydeep P Bardhan, 2007, The Journal of chemical physics.

Evaluation of an inverse molecular design algorithm in a model binding site

Bruce Tidor, David J Huggins, Michael D Altman, 2009, Proteins.

Development of a High-Throughput Gene Expression Screen for Modulators of RAS-MAPK Signaling in a Mutant RAS Cellular Context

Marc Ferrer, Michelle A Cleary, Michael D Altman, 2016, Journal of biomolecular screening.

Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.

Jongwon Lim, Michael D Altman, Craig Rosenstein, 2011, Journal of medicinal chemistry.

Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met.

Wei Lu, Michael D Altman, Craig Rosenstein, 2013, Journal of medicinal chemistry.

Design of Mutation‐resistant HIV Protease Inhibitors with the Substrate Envelope Hypothesis

Hong Cao, Bruce Tidor, Michael K Gilson, 2007, Chemical biology & drug design.

Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance.

Hong Cao, Bruce Tidor, Nese Kurt Yilmaz, 2013, Chemistry & biology.

Thiophene carboxamide inhibitors of JAK2 as potential treatments for myleoproliferative neoplasms.

Thomas Rush, Andrew M Haidle, Michael D Altman, 2014, Bioorganic & medicinal chemistry letters.

HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants.

Hong Cao, Bruce Tidor, Michael K Gilson, 2008, Journal of the American Chemical Society.

The discovery of reverse tricyclic pyridone JAK2 inhibitors. Part 2: lead optimization.

Tony Siu, Michael D Altman, Lin Xu, 2014, Bioorganic & medicinal chemistry letters.